Analyst Price Target is $69.56
▼ -3.98% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for Axonics in the last 3 months. The average price target is $69.56, with a high forecast of $79.00 and a low forecast of $57.00. The average price target represents a -3.98% upside from the last price of $72.44.
Current Consensus is
The current consensus among 7 contributing investment analysts is to buy stock in Axonics. This Buy consensus rating has held steady for over two years.
Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA.